Page last updated: 2024-10-24

regulation of B cell differentiation

Definition

Target type: biologicalprocess

Any process that modulates the frequency, rate or extent of B cell differentiation. [GOC:go_curators]

B cell differentiation is a complex process tightly regulated by a multifaceted network of signaling pathways, transcription factors, and environmental cues. This intricate orchestration ensures the proper development of diverse B cell subsets with distinct roles in immune responses.

**Commitment to the B Cell Lineage:**
- Hematopoietic stem cells (HSCs) are the progenitors of all blood cells, including B cells.
- HSCs receive signals from their microenvironment that drive them towards the lymphoid lineage.
- Transcription factors such as Ikaros, PU.1, and E2A play crucial roles in promoting lymphoid lineage commitment.
- Pre-pro-B cells, the earliest identifiable B cell progenitors, express the recombinase activating genes (RAG1 and RAG2) that initiate VDJ recombination, a process essential for generating diverse antibody repertoires.

**Pro-B Cell Stage:**
- The pro-B cell stage is characterized by the rearrangement of the heavy chain immunoglobulin (Ig) gene locus.
- RAG1 and RAG2 enzymes catalyze the recombination process, joining V, D, and J segments to generate unique heavy chain variable regions.
- Successful heavy chain rearrangement results in the expression of a pre-B cell receptor (pre-BCR) on the cell surface.
- The pre-BCR signal promotes cell survival, proliferation, and progression to the next stage.
- It also triggers allelic exclusion, ensuring that only one heavy chain allele is expressed per cell.

**Pre-B Cell Stage:**
- Pre-B cells undergo light chain gene rearrangement.
- V and J segments of the light chain locus are recombined to create unique light chain variable regions.
- Successful light chain rearrangement leads to the expression of a functional B cell receptor (BCR) on the cell surface.
- The BCR signal is essential for further B cell development and for the selection of B cells with functional, antigen-binding receptors.

**Immature B Cell Stage:**
- Immature B cells migrate from the bone marrow to the spleen, where they undergo further maturation.
- In the spleen, immature B cells are exposed to self-antigens.
- Central tolerance mechanisms ensure the elimination of self-reactive B cells, preventing autoimmune reactions.
- Surviving immature B cells become mature B cells, expressing a diverse repertoire of antigen-specific BCRs.

**Mature B Cell Subsets:**
- Mature B cells are heterogeneous and can differentiate into various effector subsets depending on the nature of the antigen encountered and the specific signaling pathways activated.
- **Plasma cells** are terminally differentiated B cells that produce and secrete large amounts of antibodies.
- **Memory B cells** are long-lived cells that retain the memory of past infections and can rapidly mount secondary immune responses upon re-exposure to the same antigen.
- **Follicular B cells** reside in the follicles of secondary lymphoid organs and participate in humoral immune responses, including germinal center formation and antibody affinity maturation.
- **Marginal zone B cells** are specialized B cells located in the marginal zone of the spleen, rapidly responding to blood-borne pathogens.

**Regulation of B Cell Differentiation:**
- B cell development is tightly regulated by a complex interplay of signaling pathways, transcription factors, and environmental cues.
- **Signaling pathways:**
- BCR signaling plays a central role in B cell differentiation, regulating cell survival, proliferation, and antibody production.
- Other critical signaling pathways include those activated by cytokines (e.g., IL-7, IL-4, IL-5), chemokines, and Toll-like receptors (TLRs).
- **Transcription factors:**
- Pax5, a master regulator of B cell identity, is essential for B cell development and function.
- Other key transcription factors include EBF1, IRF4, BLIMP1, and XBP1, which regulate distinct aspects of B cell differentiation.
- **Microenvironment:**
- The bone marrow and spleen provide specialized niches that support B cell development and differentiation.
- Interactions with stromal cells, cytokines, and chemokines in these niches influence B cell fate decisions.

**Pathological Consequences of Dysregulation:**
- Dysregulation of B cell differentiation can lead to various immune disorders, including autoimmune diseases, immunodeficiency, and malignancies.
- Aberrant B cell development can result in the production of autoreactive antibodies, leading to autoimmune disorders.
- Defects in B cell signaling pathways or transcription factors can impair immune responses, predisposing individuals to infections.
- B cell malignancies, such as lymphomas and leukemias, arise from uncontrolled proliferation and differentiation of B cells.

In summary, B cell differentiation is a highly regulated process essential for generating diverse B cell subsets with distinct functions in immune responses. This intricate process involves a complex interplay of signaling pathways, transcription factors, and environmental cues, ensuring proper B cell development and preventing immune dysregulation.'
"

Proteins (3)

ProteinDefinitionTaxonomy
Zinc finger protein AiolosA zinc finger protein Aiolos that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q9UKT9]Homo sapiens (human)
Toll-like receptor 9A Toll-like receptor 9 that is encoded in the genome of human. []Homo sapiens (human)
Tyrosine-protein phosphatase non-receptor type 6A tyrosine-protein phosphatase non-receptor type 6 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P29350]Homo sapiens (human)

Compounds (23)

CompoundDefinitionClassesRoles
5-iodo-2-(oxaloamino)benzoic acidorganoiodine compound
hydroxychloroquinehydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
glycyrrhetinic acidcyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid
immunomodulator;
plant metabolite
oleanolic acidhydroxy monocarboxylic acid;
pentacyclic triterpenoid
plant metabolite
vanadatesvanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.

Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.
trivalent inorganic anion;
vanadium oxoanion
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
ursolic acidhydroxy monocarboxylic acid;
pentacyclic triterpenoid
geroprotector;
plant metabolite
maslinic acid(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoriadihydroxy monocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
nsc-87877NSC-87877: potent Shp2 (nonreceptor protein tyrosine phosphatase) inhibitor; structure in first source
tanshinonetanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agentabietane diterpenoidanticoronaviral agent
celastrolmonocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
pomalidomide3-aminophthalimidoglutarimide: structure in first sourcearomatic amine;
dicarboximide;
isoindoles;
piperidones
angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
cryptotanshinonecryptotanshinone: from Salvia miltiorrhizaabietane diterpenoidanticoronaviral agent
tanshinone ii atashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first sourceabietane diterpenoid
lenalidomidearomatic amine;
dicarboximide;
isoindoles;
piperidones
angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
nsc-89199estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.carbamate ester;
organochlorine compound;
steroid phosphate
2-(oxaloamino)benzoic acid(oxaloamino)benzoic acid
cefsulodincefsulodin : A pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic.

Cefsulodin: A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.
cephalosporin;
organosulfonic acid;
primary carboxamide
antibacterial drug
nq301NQ301: structure in first source
nsc 117199
2-amino-6-chloropurine6-chloroguanine : An organochlorine compound that is 7H-purin-2-amine substituted by a chloro group at position 6.

6-chloroguanine: an antimalarial that inhibits hypoxanthine-guanine-xanthine phosphoribosyltransferase; structure in first source
2-aminopurines;
organochlorine compound
corosolic acidtriterpenoidmetabolite
Dihydrotanshinone Idihydrotanshinone I: extracted from Radix Salviaeabietane diterpenoidanticoronaviral agent
3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid: an SHP2 inhibitor; structure in first source